Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A CDC committee has voted to expand its respiratory syncytial virus vaccine recommendation to include all people aged 50 to ...

China is not as big a player in the manufacturing of key ingredients used to make brand and generic medicines as previously ...

A federal panel of medical experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as another option to protect teens against meningitis. The 15-member ...

Advancements in mRNA vaccine technology are reshaping medicine, addressing challenges and expanding applications from ...